| Name | Title | Contact Details |
|---|---|---|
Randall Deinhammer |
Senior R&D Manager | Profile |
Lone Dybdal Nilsson |
Vice President, Agriculture & Industrial Biosolutions R&D | Profile |
Mads Torry-Smith |
Head of Digitalization, Agriculture & Industrial Biosolutions R&D | Profile |
Kevin Cox |
R&D Director, Novozymes | Profile |
Kathryn Wiley |
CMO Manager - QES Americas | Profile |
Avadim Technologies Inc is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.
Alpine Biomed is a Fountain Valley, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Intracel Resources is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.
Learn more about Cara Therapeutics, a biotechnology company focusing on pharmaceutical product development for better pruritus and pain management.